Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP
Executive Summary
Many NDAs, BLAs and INDs for cancer drugs are being reassigned to new review divisions as part of a reorganization of FDA’s Office of Oncology Drug Products.
You may also be interested in...
FDA's Office of Medical Policy Grows Into A "Super Office"; DDMAC Gets A Promotion
The Office of Medical Policy now houses the Office of Prescription Drug Promotion (formerly DDMAC) and the newly created Office of Medical Policy Initiatives.
Genentech Restricts Population In Last-Ditch Bid To Keep Avastin's Breast Cancer Claim
Final submission from Genentech focuses on revised indication and Risk Evaluation and Mitigation Strategy to support continued approval while it conducts another confirmatory trial.